TCT 2024 Career Achievement Award to be Presented to Robert A. Harrington, MD
The TCT 2024 Career Achievement Award will be presented to Robert A. Harrington, MD, during Transcatheter Cardiovascular Therapeutics (TCT), the annual scientif
Stay updated with breaking news from Williamw Oneill. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The TCT 2024 Career Achievement Award will be presented to Robert A. Harrington, MD, during Transcatheter Cardiovascular Therapeutics (TCT), the annual scientif
The TCT 2024 Career Achievement Award will be presented to Robert A. Harrington, MD, during Transcatheter Cardiovascular Therapeutics (TCT), the annual scientif
Credit Adobe Stock Promoted in April as the first large-scale drug study on the effectiveness of hydroxychloroquine to protect against COVID-19, the Detroit-based clinical trial has quietly been iced. Henry Ford Health System officials told Bridge Michigan they could not find enough participants to continue studying whether the drug could help beat back the deadly pandemic. Hydroxychloroquine — an antimalarial drug that has also proven useful in treating rheumatoid arthritis, lupus, and other inflammatory diseases — briefly produced some excitement last spring when it was promoted as a p...
Henry Ford study on hydroxychloroquine for COVID-19 quietly shut down By Robin Erb, Bridge Michigan © GERARD JULIEN, AFP via Getty Images Hydroxychloroquine, an antimalarial drug dubbed a "gift from God" by US President Donald Trump for its potential ability to fight the new coronavirus, was found to be no more effective than standard treatment in a small Chinese study. Promoted in April as the first large-scale drug study on the effectiveness of hydroxychloroquine to protect against COVID-19, the Detroit-based clinical trial has quietly been iced. Henry Ford Health System ...